Liver and Spleen
-
Upload
lovelots1234 -
Category
Documents
-
view
39 -
download
0
Embed Size (px)
description
Transcript of Liver and Spleen

Liver and Spleen Diseases
Bernard S. Victorio, M.D., FPCS, FPSGS

at the end of the session
imaging modalities use in diagnosis of hepatobiliary, extrabiliary and spleen diseases
diagnosis and management of benign and maligntdiseases
diagnosis and management ofhepatobiliary splenic diseases
management of liver and splenic injuries

RADIOLOGIC EVALUATION
ADVANTAGE DISADVANTAGE
ULTRASOUND • Initial imaging• Biliary and liver
Intraoperative UTZ
• Incomplete imaging• Obesity/bowel

RADIOLOGIC EVALUATION
ADVANTAGE DISADVANTAGE
CT SCAN • Contrast medium• Arterial/venous phase
MRI T1/T2
PET SCAN Metastatic tumors Lack of exact localization

Infection of the liverPYOGENIC AMOEBIC
ETIOLOGY • Acute appendicitis• Impaired biliary drainage• Hematogenous• endocarditis
entamoeba
LOCATION • Single• Multiple- honeycomb• Right lobe of liver
• Single/ Multiple• Superior, anterior near
diaphragm• Necrotic central portion• Anchovy paste or chocolate
sauce
SYMPTOMS • RUQ pain, fever• Jaundice- 1/3• Leukocytosis• Increase ESR and alk phos• Elevated transaminase
• RUQ pain, fever• Jaundice, unusual• Hepatomegaly• Leukocytosis• Mildly increase AP

Infection of the liverIMAGING PYOGENIC AMOEBIC
UTZ Hypoechoic lesions with well defined borders, internal echoes
Non specific
For follow up
CT Hypodense, air fluid level
Non specificExtrahepaticinvolvementWell defined low density round lesion with wallenhancementCentral cavity with sepatations/air fluid level
For follow up
MRI High level of sensitivity*Guided biopsy

Infection of the liver
MANAGEMENT PYOGENIC AMOEBIC
CULTURE 50% of cases Flourescent antibody
ANTIBIOTIC Gram (-) (+)anaerobic
Metronidazole 750 mg TID for 7 to 10 days
DRAINAGE • Laparoscopic/open• Anatomic resection• Necrotic hepatic
malignancy
Aspiration rarely needed• Large abscess• Not responding to medical
therapy• Superinfected• Left lobe

Incidental liver mass

Liver Lesions
Benign Malignant
Cyst Hepatocellular CA
Hemangioma cholangiocarcinoma
Focal Nodular Hyperplasia Gallbladder CA
Adenoma Metastatic colorectal CA
Biliary hamartoma Metastatic neuroendocrine (carcinoid)
abscess Metastatic cancers

Benign Liver Lesions
cyst Most frequently encountered• Congenital cyst• Biliary cystadenoma• Polycystic liver disease• Caroli’s disease
Bile duct hamartoma • Small liver lesion (2 to 4 mm) surface of liver• Firm, yellow, smooth in appearance• Excisional biopsy

manifestations
Hemangioma adenoma Focal nodular hyperplasia
• Most common• Pain (larger than 5-6 cm)• Spontaneous rupture is
rare• Malignant
transformation (?)
• Young women (20 to 40)• pain• Solitary, sometimes multiple• Prior or current use of oral
contraceptive• Spontaneous rupture (10-
25%)• Malignant transformation to
HCC
• Childbearing• Oral conceptive use • Do not rupture• No significant risk of
malignant transformation

CT scan Hemangioma adenoma Focal nodular hyperplasia
Large – asymmetrical nodular peripheral enhancement,isodense
Sharply defined border, confused with metastatic tumors• Venous phase –
hypodense/isodense• Arterial phase – subtle
hypervascular enhancementhypodense
• Biphasic, well circumscribe with a typical central scar
• intense homogenous enhancement on arterial phase contrast images, often isodense or invisible compared with background liver on venous phase

MRI
Hemangioma adenoma Focal nodular hyperplasia
Hypointense on T1 and hyperintense on T2
Hyperintense on T1 and enhance early after gadolinium
Hypointense on T1 and isointense to hypointense on T2Godolinium, become hyperintense but become hypointense on delayed images
Nuclear imaging “cold” Radionuclide sulfur colloid

Management
Hemangioma adenoma Focal nodular hyperplasia
• Liver biopsy – with caution, increase risk of bleeding
• Main indication for resection – pain
• Enucleation• formal hepatic resection
• resection Main indication for surgery is abdominal painOral contraceptive or estrogen should be stopped

Malignant Liver Tumor
Hepatocellular Carcinoma
Risk factors Viral hepatitisAlcoholic hepatitisHemochromatosisNonalcoholic steatohepatitis
CT scan Hypervascular in arterial phase and hypodenseduring the delayed phase
MRI Variable T1 and hyperintense T2
Portal vein thrombosis Highly suggestive

Algorithm for HCC

Cholangiocarcinoma 2nd most common
Hilar (klatskin) Peripheral
Obstructive jaundice, painless Tumor mass
locoregional
• Surgical resection (absence of PSC)• chemoradiation
Poor survival• Vascular invasion• Positive margins• Multiple tumors
Improved outcome• Histologic negative margin• Concomitant hepatic resection• Well differentiated
Prognostic factors affecting survival• Absence of mucobilia• Nonpapillary tumor• Advance stage• Nonhepatectomy• Lack of pre-op chemo
3 to 5 year survival : 41.7% to 26.8% 3 year survival: 55

Gallbladder CA
• Rare, aggressive tumor• Poor prognosis• Associated with cholelithiasis
Diagnosis• Pre-op : 57%• Intra-op: 11%• Incidental: 32%
Surgical approach • Re-op for incidental gallbladder CA after choleycstectomy
• Beyond stage 1 (T2 and T3)• Central liver resection• Hilar lymphadenopathy• Evaluation of cystic duct stump
• Radical resection with advance disease• Role of formal lobectomy/extended
lobectomy (?)

Metastatic colo-rectal CA
Resection on fewer than 4 10 year survival• 4 or more : 29%• Solitary: 33%
Resectability is no longer defined on what actually is removed but on what will remain after resection
• Use of neoadjuvant chemotherapy• Portal vein embolization• Simultaneous ablation• Resection of extra-hepatic tumor

Mets from Neuroendocrine tumor Other metastatic tumor
Protacted natural historyDebilitating endocrinopathy
• Breast• Renal• Other Gi
2 stage procedurePrimary tumor is resected• Resection with limited resection of
left hemiliver, portal vein ligation• 8 weeks, right or extended right
hepatectomy
• 2, 5, 8 overall survival rate:94%, 94$, 79%
• Disease free survival rates:85%, 50%, 26%

treatment option
option
Hepatic resection Gold standardHCC with cirrhosis (?)Margin: 1cm
Liver transplantation HCC with cirrhosisRecurrent rates (>50%)Improved survival rate• Early stage (stage 1 or 2)• One tumor, 5cm• Three tumor largest 3cm• Absence of gross vascular invasion
or extrahepatic spread

option
Radiofrequency ablation • HCC of 3 to 7.5 cm• Recurrence rate after resection
(44% vs 11%)• Combination with TACE
Ethanol ablation, cryosurgery,microwave ablation
chemoembolization
Yttrium 90 micropheres Inoperable primary or metastatic liver tumor
Stereotactic radiosurgery
Systemic chemotherapy

Surgical techniques


Acute Liver Failure
Etiology Viral infection (hepatis a, b, e)
Drug induce (acetaminophen)
Clinical PresentationJaundice and encephalopathy
Hepatic coma
Increase creatinine
Arterial ph <7.30
Culture proven infection

ALF
Liver biopsy
Rapid progression
Acetaminophen overdoseActivated charcoal
N-acetylcysteine
ICU
Prognosis

CIRRHOSIS
History and PE
Lab findings Mild normochromic anemiaLow WBC, platelet Bone marrow – macronormoblasticProlong PT, not responding to vitamin KBilirubin, transamines, alk phos -elevated
Liver biopsy UTZ or CT guided percutaneous biopsy

Assessment of surgical risk(Child-Turcotte-Pugh Score)
variable 1 point 2 points 3 points
bilirubin <2mg/dl 2-3mg/dl >3m/dl
albumin >3.5 g/dl 2.8-3.5 g/dl <2.8 g/dl
INR <1.7 1.7 -2.2 >2.2
encephalopathy none controlled uncontrollable
ascites none controlled uncontrollable
Class
A- 5-6 points
B- 7-9 points
C – 10-15 points

PORTAL HYPERTENSION
Gastroesophageal varices
Splenomegaly
Caput medusae (cruveilhier-baumgarten murmur)
Ascitis
Anorectal varices

management
Esophageal Varices
Prevention of Variceal bleeding Abstinence from alcoholAvoidance of aspirin and NSAIDAdminstration of propranololProphylactic endoscopic variceal ligation (EVL)
Acute Variceal Bleeding(5 day hemostasis rate)
• Blood resuscitation• Fresh-frozen plasma and platelet• Prophylactic antibiotics• Vasopressin (0.2 to 0.8 units/min)• Somatostin (initial bolus 50μ/IV)• EVL• Surgical shunt/TIPs (refractory variceal bleeding)• Balloon tamponade (<24 hours)

shuntsShunts
Aim Reduce portal venous pressureMaintain total hepatic and portal blood flowAvoid a high incidence of complicating hepatic encephalopathy
Portocaval shunt Higher incidence of shunt thrombosis and rebleedingHigh incidence of encephalopathy
Warren shunt (distal splenorenal) Lower rate of hepatic encephalopathy and decompensation
Transjugular Intrahepatic PortosystemicShunt (TIPS)
>90% of cases refractory to medical treatment

Non shunt procedure
Suguira
Extrahepatic portal vein thrombosis and refractory bleeding
• Extensive devascularization of the stomachand distal esophagus
• Transection of the esophagus• Splenectomy• Truncal vagotomy• pyloroplasty
Hepatic transplant
Patients only chance of definitive therapy and long term survivalPatient with variceal bleeding refractory to all forms of managementReverses most of the hemodynamic and humoralchanges associated with cirrhosis
Not affected by previous EVL, TIPS, splenorenal, mesocaval shunts

Splenic Diseases

Radiologic Evaluation
ADVANTAGE DISADVANTAGE
ULTRASOUND • First imaging modality• Pre-op planning
Risk of hemorrhage during percutaneous ultrasound guided procedures
CT SCAN • High degree of resolution• Invaluable tool in
evaluation and management of splenic trauma
• Splenomegay, solid/cystic• Percutaneous procedures
Plain radiography Outline of spleen

ADVANTAGE DISADVANTAGE
MRI Excellent detail and versatility No obvious advantageMore expensive
Angiography Therapeutic splenic arterial embolization (SLE)• Localization and treatment of
hemorrhage in trauma pt• Delivery of therapy in patients
with cirrhosis/portal/transplant pt
• Adjunt to splenectomy
PancreatitisRisk of invasive procedure
Nuclear imaging Locating accessory spleen
Splenic index 120 ml to 480 ml

Indications for splenectomy
Splenic rupture
RBC disorder and hemoglobinopathies
WBC disorder
Platelet disorder
Bone marrow disorder
Cyst/tumors
Infections and abscess
Infiltrative disorder



Pre-op consideration
vaccination Overwelming Postsplenectomy infectionEncapsulated bacteria, 2 weeks elective surgery• Streptococcus pneumoniae• H. Influenza• Meningococcus
Splenic artery embolization Reduce spleen size
Deep vein thrombosis prophylaxis Portal vein thrombosis• Anorexia• Abdominal pain• Leukocytosis• ThrombocytosisSequential compression deviceHeparin (5000 I.U)

post splenectomy outcomesComplications
Left lower lobe atelectasis, most common
Subphrenic hematoma
Subphrenic abscess
Pancreatitis, psedocyst, pancreatic fistula
Thromboembolic
Hematologic
Initial response – rise in platelet count
Increase in hemoglobin to 10g/dl

OPSI
Medical emergencyProgress to bacteric septic shock, with hypotension, anuria, DIC
More common in hematologic diseases
<5 years of age and >50 years of age
PathogenesisLoss of splenic macrophagesDiminish tuftsin prodcutionLoss of spleen reticuloendothelial function

vaccination
Pneumococcus and other encapsulated
2 weeks before planned surgery
With 7 to 10 days of emergent splenectomy
OPSI casesPneumococcus
Meningococcus
H. influenza type B
group A Streptococci

Trauma


Thank you